Potential role of odanacatib in the treatment of osteoporosis

Clinical Interventions in Aging

Volumn 7, Issue , 2012, Pages 235-247

  Ng, Kong Wah ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Bone remodeling; Bone turnover markers; Cathepsin K; Inhibitors; Osteoclast; Selective cathepsin

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BALICATIB; CATHEPSIN K; CATHEPSIN K INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L 006235; ODANACATIB; ONO 5334; OSTEOCLAST DIFFERENTIATION FACTOR; PARACETAMOL; PARATHYROID HORMONE[1-34]; PLACEBO; RELACATIB; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTHRALGIA; BACKACHE; BONE DISEASE; BONE REMODELING; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIMB PAIN; LUNG DISEASE; METASTASIS; MORPHEA; NONHUMAN; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHARMACOLOGICAL BLOCKING; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SKIN DISEASE; SKIN TOXICITY; TREATMENT DURATION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; PHYSIOLOGY; RABBIT; RHESUS MONKEY;

ANIMALS; BIPHENYL COMPOUNDS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CATHEPSIN K; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MACACA MULATTA; OSTEOPOROSIS, POSTMENOPAUSAL; RABBITS;

EID: 84871692621     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S26729     Document Type: Review

References (130)

1. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am. 2003;32(1):253-271.
2. Khosla S, Burr D, Cauley J, etal; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-1491.
3. Shane E, Burr D, Ebeling PR, etal; American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-2294.
4. Vahle JL, Sato M, Long GG, etal. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312-321.
5. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab. 2012;97(2):311-325.
6. Martin TJ, Sims NA, Ng KW. Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int. 2008;19(8):1125-1138.
7. Walker EC, McGregor NE, Poulton IJ, etal. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008;23(12):2025-2032.
8. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A. 2008;105(52):20764-20769.
9. Negishi-Koga T, Shinohara M, Komatsu N, etal. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;12(11):1473-1480.
10. Tang Y, Wu X, Lei W, etal. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7):757-765.
11. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677-692.
12. Zhao C, Irie N, Takada Y, etal. Bidirectional ephrinB2-EphB4signaling controls bone homeostasis. Cell Metab. 2006;4(2):111-121.
13. Martin TJ, Allan EH, Ho PW, etal. Communication between ephrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol. 2010;658:51-60.
14. Sims NA. EPHs and ephrins: many pathways to regulate osteoblasts and osteoclasts. Bonekey Osteovision. 2010;7(9):304-313.
15. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008;118(2):421-428.
16. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570-578.
17. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353(6):595-603.
18. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):3318-3325.
19. Black DM, Delmas PD, Eastell R, etal; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
20. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359(9322):2018-2026.
21. Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol. 2011;7(11):631-638.
22. Neer RM, Arnaud CD, Zanchetta JR, etal. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.
23. Bauer DC, Garnero P, Bilezikian JP, etal. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006;91(4):1370-1375.
24. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351(27):2839-2849.
25. Zhao H, Kitaura H, Sands MS, Ross FP, Teitelbaum SL, Novack DV. Critical role of beta3integrin in experimental postmenopausal osteoporosis. J Bone Miner Res. 2005;20(12):2116-2123.
26. Marzia M, Sims NA, Voit S, etal. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000;151(2):311-320.
27. Schaller S, Henriksen K, Sørensen MG, Karsdal MA. The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment. Drug News Perspect. 2005;18(8):489-495.
28. Brockstedt H, Bollerslev J, Melsen F, Mosekilde L. Cortical bone remodeling in autosomal dominant osteopetrosis: a study of two different phenotypes. Bone. 1996;18(1):67-72.
29. Del Fattore A, Peruzzi B, Rucci N, etal. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet. 2006;43(4):315-325.
30. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010;120(10):3421-3431.
31. Brömme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler. 1995;376(6):379-384.
32. Gauthier JY, Chauret N, Cromlish W, etal. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008;18(3):923-928.
33. Rodan SB, Duong LT. Cathepsin K-a new molecular target for osteoporosis. Bonekey Osteovision. 2008;5(1):16-24.
34. Yamaza T, Goto T, Kamiya T, Kobayashi Y, Sakai H, Tanaka T. Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur. Bone. 1998;23(6):499-509.
35. Vääräniemi J, Halleen JM, Kaarlonen K, etal. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res. 2004;19(9):1432-1440.
36. Xia L, Kilb J, Wex H, etal. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem. 1999;380(6):679-687.
37. Garnero P, Borel O, Byrjalsen I, etal. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273(48):32347-32352.
38. Furuyama N, Fujisawa Y. Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts. Steroids. 2000;65(7):371-378.
39. Troen BR. The regulation of cathepsin K gene expression. Ann N Y Acad Sci. 2006;1068:165-172.
40. Fujisaki K, Tanabe N, Suzuki N, etal. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9in osteoclast precursor RAW264.7cells. Life Sci. 2007;80(14):1311-1318.
41. Maroteaux P, Lamy M. 2 cases of a condensing osseous disease: pycnodysostosis. Arch Fr Pediatr. 1962;19:267-274. French.
42. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236-1238.
43. Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med. 2002;2(5):407-421.
44. Nishi Y, Atley L, Eyre DE, etal. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res. 1999;14(11):1902-1908.
45. Saftig P, Hunziker E, Wehmeyer O, etal. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95(23):13453-13458.
46. Gowen M, Lazner F, Dodds R, etal. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14(10):1654-1663.
47. Chen W, Yang S, Abe Y, etal. Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet. 2007;16(4):410-423.
48. Pennypacker B, Shea M, Liu Q, etal. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone. 2009;44(2):199-207.
49. Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res. 2001;16(8):1444-1452.
50. Yamashita DS, Dodds RA. Cathepsin K and the design of inhibitors of cathepsin K. Curr Pharm Des. 2000;6(1):1-24.
51. Tavares FX, Boncek V, Deaton DN, etal. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. J Med Chem. 2004;47(3):588-599.
52. Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009;18(5):585-600.
53. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733-759.
54. Falgueyret JP, Desmarais S, Oballa R, etal. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005;48(24):7535-7543.
55. Black WC, Percival MD. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. Chembiochem. 2006;7(10):1525-1535.
56. Desmarais S, Black WC, Oballa R, etal. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol. 2008;73(1):147-156.
57. Li CS, Deschenes D, Desmarais S, etal. Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg Med Chem Lett. 2006;16(7):1985-1989.
58. Kim TS, Tasker AS. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis. Curr Top Med Chem. 2006;6(4):355-360.
59. Marquis RW, Ru Y, LoCastro SM, etal. Azepanone-based inhibitors of human and rat cathepsin K. J Med Chem. 2001;44(9):1380-1395.
60. Podgorski I. Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem. 2009;1(1):21-34.
61. Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther. 2008;83(1):172-176.
62. Palmer JT, Bryant C, Wang DX, etal. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J Med Chem. 2005;48(24):7520-7534.
63. Kumar S, Dare L, Vasko-Moser JA, etal. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone. 2007;40(1):122-131.
64. Yamashita DS, Marquis RW, Xie R, etal. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem. 2006;49(5):1597-1612.
65. Stroup G, Jerome C, Yamashita DS, Kumar S. Histomorphometric and biochemical evidence for a cortical bone-forming effect of a cathepsin K inhibitor in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2005;20(Suppl 1):Abstract F236.
66. Stroup GB, Dare L, Vasko-Moser J, Hoffman S, Kumar S. Repeat daily dosing with a high potent inhibitor of cathepsin K results in significant, transient elevation of plasma PTH in cynomolgus monkeys. J Bone Miner Res. 2006;21(Suppl 1):Abstract SA236.
67. Black WC. Peptidomimetic inhibitors of cathepsin K. Curr Top Med Chem. 2010;10(7):745-751.
68. Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2011;22(12):3001-3011.
69. Adami S, Supronik J, Hala T, etal. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res. 2006;21(Suppl 1):Abstract S24.
70. Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008;59(1):125-129.
71. Yamada H, Mori, Nakanishi Y, etal. Orally active cathepsin K inhibitor, ONO-5344, potently improved bone mineral density not only in trabecular bone but also in cortical bone in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2009;24(Suppl 1):Abstract SA042.
72. Yamada H, Mori H, Kunishige A, etal. Efficacy of ONO-5344, a cathepsin K inhibitor, on bone mass and strength in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2010;25(Suppl 1):Abstract SA0438.
73. Eastell R, Nagase S, Ohyama M, etal. Safety and efficacy of the cathepsin K inhibitor ONO-5334in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res. 2011;26(6):1303-1312.
74. Pennypacker B, Rodan S, Masarachia P, Rodan G, Kimmel DB. Bone effects of a cathepsin K inhibitor in the adult estrogen-deficient rabbit. J Bone Miner Res. 2006;21(Suppl 1):Abstract S383.
75. Masarachia PJ, Pennypacker BL, Pickarski M, etal. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27(3):509-523.
76. Cusick T, Chen CM, Pennypacker BL, etal. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012;27(3):524-537.
77. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem. 2004;50(5):883-890.
78. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52(9-10):499-509.
79. Pennypacker B, Wu G, Korn R, Samadfam R, Smith SY, Duong LT. Efficacy of the combination of parathyroid hormone plus odanacatib or alendronate, as compared to the monotherapies in estrogen-deficient rabbits. J Bone Miner Res. 2011;26(Suppl 1):Abstract 1030.
80. Stoch SA, Miller DL, Van Dyck K, etal. Effect of cathepsin K inhibition on bone resorption markers in healthy postmenopausal women. J Bone Miner Res. 2006;21(Suppl 1):Abstract 1224.
81. Stoch SA, Zajic S, Stone J, etal. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009;86(2):175-182.
82. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7(8):447-456.
83. Harris ST, Gertz BJ, Genant HK, etal. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 1993;76(6):1399-1406.
84. Schnitzer T, Bone HG, Crepaldi G, etal. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12(1):1-12.
85. Bone HG, McClung MR, Roux C, etal. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937-947.
86. Lewiecki EM. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. IDrugs. 2009;12(12):799-809.
87. Eisman JA, Bone HG, Hosking DJ, etal. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2):242-251.
88. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone. 2002;30(4):599-603.
89. Bone HG, Bolognese MA, Yuen CK, etal. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-980.
90. Miller PD, Bolognese MA, Lewiecki EM, etal. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229.
91. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009;94(2):538-544.
92. Binkley N, Gilchrist N, Langdahl B, etal. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. J Bone Mineral Res. 2011;26(Suppl 1):Abstract FR0453.
93. Littlewood-Evans A, Kokubo T, Ishibashi O, etal. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone. 1997;20(2):81-86.
94. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun. 1995;206(1):89-96.
95. Bühling F, Waldburg N, Gerber A, etal. Cathepsin K expression in human lung. Adv Exp Med Biol. 2000;477:281-286.
96. Rünger TM, Quintanilla-Dieck MJ, Bhawan J. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J Invest Dermatol. 2007;127(2):293-297.
97. Hou WS, Li Z, Gordon RE, etal. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol. 2001;159(6):2167-2177.
98. Littlewood-Evans AJ, Bilbe G, Bowler WB, etal. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997;57(23):5386-5390.
99. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res. 2003;18(2):222-230.
100. Everts V, Hou WS, Rialland X, etal. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int. 2003;73(4):380-386.
101. Bühling F, Röcken C, Brasch F, etal. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol. 2004;164(6):2203-2216.
102. Srivastava M, Steinwede K, Kiviranta R, etal. Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. Respir Res. 2008;9:54.
103. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Rünger TM. Expression and regulation of cathepsin K in skin fibroblasts. Exp Dermatol. 2009;18(7):596-602.
104. Tepel C, Brömme D, Herzog V, Brix K. Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci. 2000;113(Pt 24):4487-4498.
105. Friedrichs B, Tepel C, Reinheckel T, etal. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest. 2003;111(11):1733-1745.
106. Dauth S, Sîrbulescu RF, Jordans S, etal. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. BMC Neurosci. 2011;12:74.
107. Lecaille F, Chowdhury S, Purisima E, Brömme D, Lalmanach G. The S2 subsites of cathepsins K and L and their contribution to collagen degradation. Protein Sci. 2007;16(4):662-670.
108. Isabel E, Bateman KP, Chauret N, etal. The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. Bioorg Med Chem Lett. 2010;20(3):887-892.
109. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664.
110. Eastell R. Breast cancer and the risk of osteoporotic fracture: A paradox. J Clin Endocrinol Metab. 2007;92(1):42-43.
111. Gnant M, Mlineritsch B, Schippinger W, etal; ABCSG-12 Trial Investigators, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-691.
112. Brufsky AM, Bosserman LD, Caradonna RR, etal. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77-85.
113. Ellis GK, Bone HG, Chlebowski R, etal. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3study. Breast Cancer Res Treat. 2009;118(1):81-87.
114. Santen RJ. Clinical review: Effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab. 2011;96(2):308-319.
115. Jensen AB, Wynne C, Ramirez G, etal. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010;10(6):452-458.
116. Salminen-Mankonen HJ, Morko J, Vuorio E. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets. 2007;8(2):315-323.
117. Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005;57(7):973-993.
118. Morko J, Kiviranta R, Joronen K, Säämänen AM, Vuorio E, Salminen-Mankonen H. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum. 2005;52(12):3713-3717.
119. Cummings SR, San Martin J, McClung MR, etal; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
120. Bone HG, Bolognese MA, Yuen CK, etal. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149-2157.
121. Sosa M, Hernández D, Segarra MC, Gómez A, de la Peña E, Betancor P. Effect of two forms of alendronate administration upon bone mass after two years of treatment. J Clin Densitom. 2002;5(1):27-34.
122. Duong LT. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Reports. 2012:1. doi:10.1038/bonekey.2012.67.
123. Khosla S. Odanacatib: location and timing are everything. J Bone Miner Res. 2012;27(3):506-508.
124. Balena R, Shih MS, Parfitt AM. Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res. 1992;7(12):1475-1482.
125. Fratzl-Zelman N, Valenta A, Roschger P, etal. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab. 2004;89(4):1538-1547.
126. Bauer DC. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow? J Bone Miner Res. 2011;26(2):239-241.
127. Black DM, Greenspan SL, Ensrud KE, etal; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349(13):1207-1215.
128. Merck. A study of MK0822in postmenopausal women with osteoporosis to assess fracture risk (MK-0822-018AM4 EXT). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2007 [updated March 16, 2012]. Available from: clinicaltrials. gov/ct2/show/NCT00529373. NLM identifier: NCT00529373. Accessed June 6, 2012.
129. Merck. BMD efficacy and safety of odanacatib in postmenopausal women (0822-031). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2008 [updated May 14, 2012]. Available from: clinicaltrials. gov/ct2/show/NCT00729183. NLM identifier: NCT00729183. Accessed June 6, 2012.
130. Merck. A study to assess safety and efficacy of odanacatib (MK-0822) in men with osteoporosis (MK-0822-053AM1). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated July 14, 2011]. Available from: clinicaltrials. gov/ct2/show/NCT01120600. NLM identifier: NCT01120600. Accessed June 6, 2012.